JP2023547274A5 - - Google Patents

Info

Publication number
JP2023547274A5
JP2023547274A5 JP2023549131A JP2023549131A JP2023547274A5 JP 2023547274 A5 JP2023547274 A5 JP 2023547274A5 JP 2023549131 A JP2023549131 A JP 2023549131A JP 2023549131 A JP2023549131 A JP 2023549131A JP 2023547274 A5 JP2023547274 A5 JP 2023547274A5
Authority
JP
Japan
Prior art keywords
compound
mir
salt
nucleosides
guide chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547274A (ja
Filing date
Publication date
Priority claimed from GBGB2016863.9A external-priority patent/GB202016863D0/en
Application filed filed Critical
Publication of JP2023547274A publication Critical patent/JP2023547274A/ja
Publication of JP2023547274A5 publication Critical patent/JP2023547274A5/ja
Pending legal-status Critical Current

Links

JP2023549131A 2020-10-23 2021-10-25 マイクロrna-29の化合物、組成物、および治療法における使用 Pending JP2023547274A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2016863.9 2020-10-23
GBGB2016863.9A GB202016863D0 (en) 2020-10-23 2020-10-23 Microrna-29 compounds, compositions and uses in therapy
PCT/EP2021/079580 WO2022084561A2 (en) 2020-10-23 2021-10-25 Microrna-29 compounds, compositions and uses in therapy

Publications (2)

Publication Number Publication Date
JP2023547274A JP2023547274A (ja) 2023-11-09
JP2023547274A5 true JP2023547274A5 (cg-RX-API-DMAC7.html) 2024-11-01

Family

ID=73726994

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549131A Pending JP2023547274A (ja) 2020-10-23 2021-10-25 マイクロrna-29の化合物、組成物、および治療法における使用

Country Status (9)

Country Link
US (1) US20240390410A1 (cg-RX-API-DMAC7.html)
EP (1) EP4232580A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023547274A (cg-RX-API-DMAC7.html)
KR (1) KR20230088810A (cg-RX-API-DMAC7.html)
CN (1) CN116744942A (cg-RX-API-DMAC7.html)
AU (1) AU2021365394A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195977A1 (cg-RX-API-DMAC7.html)
GB (1) GB202016863D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022084561A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4634386A4 (en) * 2022-12-16 2026-08-12 Mirscience Therapeutics Servicos De Pesquisa E Desenvolvimento Ltda Antisense oligonucleotide analogues of MIR-29 and their uses
AU2023445724A1 (en) * 2023-04-28 2025-11-06 Causeway Therapeutics Limited Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400598D0 (en) 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing
DK3149172T3 (en) * 2014-05-29 2018-08-20 Quark Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE PREVENTION OF ISKEMIC REPERFUSION LESSON IN BODIES
CN107108685B (zh) * 2014-09-08 2020-10-20 米拉根医疗股份有限公司 miR-29模拟物及其用途
GB201503967D0 (en) * 2015-03-09 2015-04-22 Univ Glasgow Biocompatible implants for use in tendon therapy
WO2020181130A2 (en) * 2019-03-05 2020-09-10 MiRagen Therapeutics, Inc. Polynucleotide conjugates and uses thereof

Similar Documents

Publication Publication Date Title
Agrawal et al. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
JP2656938B2 (ja) dsRNAと逆転写酵素インヒビターを含んで成るHIV感染治療のための医薬組成物
DE102006007433A1 (de) Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
EP2849760B1 (en) Oligonucleotide chelate complex methods
TWI740866B (zh) 肽寡核苷酸結合物
JP7697889B2 (ja) アルファ-1アンチトリプシン欠乏症(aatd)の治療法
JPH10507635A (ja) 遺伝子発現をダウンレギュレートするための2’−置換オリゴヌクレオチドの使用
JP2022536495A5 (cg-RX-API-DMAC7.html)
JP2005512976A5 (cg-RX-API-DMAC7.html)
JP2019525918A5 (cg-RX-API-DMAC7.html)
JP2022533358A5 (cg-RX-API-DMAC7.html)
EP2207555B1 (en) Oligonucleotides for the treatment or alleviation of edema
JPH11513992A (ja) シチジンデアミナーゼまたはデオキシシチジンデアミナーゼの過剰発現を伴う疾患を治療するための薬剤および方法
JP2024544532A5 (cg-RX-API-DMAC7.html)
US20260103703A1 (en) siRNA COMPOSITIONS AND METHODS TARGETING ALPHA-SYNUCLEIN NUCLEIC ACIDS
EP1935428A1 (en) Oligonucleotide-polymer conjugates
US6667293B1 (en) Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response
TW202612708A (zh) 組合治療
TW202237189A (zh) 具有增強之肝靶向的s抗原運輸抑制寡核苷酸聚合物之接合物
CN116744942A (zh) Microrna-29化合物、组合物及其治疗用途
JP2025504474A5 (cg-RX-API-DMAC7.html)
KR102690306B1 (ko) SARS-CoV-2 증식억제효과를 보이는 TIS-L 표적 안티센스 올리고뉴클레오타이드
CN114127292A (zh) 减轻反义核酸的毒性的方法
US20030099959A1 (en) Cooperative oligonucleotides
RU2025125558A (ru) Способы лечения нарушений нервной системы